TD Cowen downgraded Keros Therapeutics (KROS) to Hold from Buy after the company voluntarily halted dosing in the 3.0 mg/kg and 4.5 mg/kg treatment arms in the ongoing TROPOS Phase 2 clinical trial of ...

Keros Therapeutics Inc (NASDAQ:KROS) released topline data from the TROPOS Phase 2 trial of cibotercept (KER-012) in combination with background therapy in patients with pulmonary arterial ...

A month after halting dosing in two of the three treatment arms of a phase 2 trial of its pulmonary arterial hypertension drug, Keros Therapeutics has now pulled the plug on the study entirely. The ...

Keros Therapeutics (NASDAQ:KROS) shares fell on Thursday after the company said it is discontinuing a Phase 2 trial designed to test cibotercept its treatment for pulmonary arterial hypertension. The ...

On Thursday, Oppenheimer adjusted its price target on Keros Therapeutics (NASDAQ:KROS) shares, reducing it significantly to ...

Keros Therapeutics (NASDAQ:KROS) has announced agreements to repurchase all shares of its common stock beneficially owned by each of ADAR1 Capital Management and Pontifax Venture Capital at a purchase ...